| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SOLARA Stock Overview
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India.
Solara Active Pharma Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹384.10 |
| 52 Week High | ₹1,749.00 |
| 52 Week Low | ₹320.00 |
| Beta | 0.49 |
| 1 Month Change | 8.11% |
| 3 Month Change | -13.54% |
| 1 Year Change | -77.67% |
| 3 Year Change | -8.45% |
| 5 Year Change | n/a |
| Change since IPO | 52.57% |
Recent News & Updates
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Does the August share price for Solara Active Pharma Sciences Limited ( NSE:SOLARA ) reflect what it's really worth...
Shareholder Returns
| SOLARA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.8% | -0.4% | 1.4% |
| 1Y | -77.7% | -12.8% | 8.2% |
Return vs Industry: SOLARA underperformed the Indian Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: SOLARA underperformed the Indian Market which returned 8.1% over the past year.
Price Volatility
| SOLARA volatility | |
|---|---|
| SOLARA Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SOLARA is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SOLARA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 2,254 | Jithesh Devendra | https://www.solara.co.in |
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support.
Solara Active Pharma Sciences Limited Fundamentals Summary
| SOLARA fundamental statistics | |
|---|---|
| Market Cap | ₹13.83b |
| Earnings (TTM) | -₹1.25b |
| Revenue (TTM) | ₹11.93b |
1.2x
P/S Ratio-11.1x
P/E RatioIs SOLARA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOLARA income statement (TTM) | |
|---|---|
| Revenue | ₹11.93b |
| Cost of Revenue | ₹7.25b |
| Gross Profit | ₹4.68b |
| Other Expenses | ₹5.93b |
| Earnings | -₹1.25b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -34.65 |
| Gross Margin | 39.22% |
| Net Profit Margin | -10.45% |
| Debt/Equity Ratio | 67.9% |
How did SOLARA perform over the long term?
See historical performance and comparison